WuXi XDC Cayman Inc.

Research WuXi XDC Cayman Inc. (L74) on Bullrun: market cap EUR 9.75B, P/E 55.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 9.75B; P/E is 55.0.

Peer valuation comparison

Latest P/E is 55x versus a Healthcare sector median of 24.46x (124.9% above).

Latest P/E is 55x versus a China median of 10.67x (415.3% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CNY 5.94BCNY 1.48BCNY 523.52M36.0%1.12CNY 1.51BCNY 879.14MCNY 10.73B
FY2024CNY 4.05BCNY 1.07B-CNY 787.95M30.6%0.83CNY 1.93BCNY 496.43MCNY 6.64B
FY2023CNY 2.12BCNY 283.54M-CNY 206.52M26.3%0.26CNY 4.05BCNY 2.84MCNY 5.45B
FY2022CNY 990.42MCNY 155.73MCNY 50.43M26.4%0.13CNY 334.97MCNY 77.18MCNY 1.48B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23EUR 9.75B55.0n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About WuXi XDC Cayman Inc.

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is WuXi XDC Cayman Inc.'s market cap?

WuXi XDC Cayman Inc.'s market capitalization is EUR 9.75B.

What is WuXi XDC Cayman Inc.'s P/E ratio?

WuXi XDC Cayman Inc.'s price-to-earnings (P/E) ratio is 55.0.

What does WuXi XDC Cayman Inc. do?

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs.